Karen Gawel
Internal Medicine · Grand Rapids, MINPI 1497702799
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $482 and has fallen 85.2% since, to $71 in 2025.
Across 84 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$206
- Amgen$177
- Boehringer Ingelheim$158
- AstraZeneca$127
- Novartis$114
- Biohaven Pharmaceutical Holding Company Ltd.$95
- plus $687 from 20 others
What the payments were for
- Food & beverage$1,564100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $206 |
| Amgen | 10 | $177 |
| Boehringer Ingelheim | 8 | $158 |
| AstraZeneca | 7 | $127 |
| Novartis | 5 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $95 |
| Pfizer | 4 | $74 |
| Lilly USA, LLC | 5 | $71 |
| Bayer | 4 | $67 |
| AbbVie | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Dexcom, Inc. | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $14 |
How this compares
$1,564 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 39 | $598 |
| Levothyroxine Sodium | 27 | $385 |
| Carvedilol | 11 | $297 |
| Rosuvastatin Calcium | 16 | $233 |
| Metoprolol Succinate | 12 | $232 |
| Losartan Potassium | 11 | $207 |
| Lisinopril | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Grand Rapids
- Robert SelfeGrand Rapids$238K
- Celia EganGrand Rapids$54K
- Jeremy GentileGrand Rapids$44K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.